



Biocon Limited

20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

September 3, 2020

To, The Manager BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To, The Manager National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex, Mumbai – 400 050
Scrip Code- 532523	Scrip Symbol- Biocon

Subject: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/ Madam,

Further to our intimation dated August 3, 2020, in relation to execution of a share subscription agreement (“**SSA**”) and a shareholders’ agreement (“**SHA**”) between Biocon Limited (the “**Company**”), Biocon Biologics India Limited (“**BBIL**”), Activ Pine LLP (“**Existing Investor**”) and Tata Capital Growth Fund II (“**Investor**”) as applicable, we wish to inform you that the subscription money aggregating to Rs. 225 Crores have been received by BBIL from the Investor.

Consequently, the Board of BBIL has approved the allotment of 88,30,456 (Eighty Eight Lakh Thirty Thousand Four Hundred Fifty Six) equity shares of Rs. 10/- each at an issue price of Rs. 254.80/- per equity share (including a premium of Rs. 244.80/- per equity share) to the Investor.

This intimation is being made in compliance with Regulations 30, read with Schedule III and other applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time (“**SEBI Listing Regulations**”).

We request you to take this on record and that the same be treated as compliance under the applicable regulation(s).

Thanking you,

Yours faithfully,

For **Biocon Limited**



Mayank Verma
Company Secretary and Compliance Officer